Page 8 of 8, showing 18 records out of 368 total, starting on record 351, ending on 368
| Publication |
Category |
Year |
|
725. Labrie, F., Koutsilieris, M. (2008) The 12th International Congress on Hormonal Steroids and Hormones & Cancer. J Steroid Biochem Mol Biol, 108: 179. |
Prostate Cancer |
2008 |
|
806. El-Alfy, M., Luu-The, V., Huang, X.F., Berger, L., Labrie, F., Pelletier, G. (1999) Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology, 140: 1481-1491. |
Prostate Cancer |
1999 |
|
4683. Spitz, I.M., Chertin, B., Fridmans, A., Farkas, A., Bélanger, A., Hartman, H., Labrie, F. (2009). Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists. Prostate Cancer Prostatic Dis, 12: 100-103. |
Prostate Cancer |
2009 |
|
4687. Ma, C., Yoshioka, M., Boivin, A., Belleau, P., Gan, L., Takase, Y., Labrie, F., St-Amand, J. (2008) Erratum: Prostate specific genes and their regulation by dihydrotestosterone. Prostate, 68: 1372. |
Prostate Cancer |
2008 |
|
4692. Labrie, F., Cusan, L., Gomez, J.L., Martel, C., Bérubé, R., Bélanger, P., Bélanger, A., Vandenput, L., Mellström, D., Ohlsson, C. (2009) Comparable Amounts of Sex Steroids are Made Outside the Gonads in Men and Women: Strong Lesson for Hormone Therapy of Prostate and Breast Cancer, JSBMB, 113: 52-56. |
Prostate Cancer |
2009 |
|
4694. Labrie, F. (2008) Comment to: Prostate specific antigen (PSA)-based screening. Int J Urol, 15: 757-762. |
Prostate Cancer |
2008 |
|
4699. Ma, C., Yoshioka, M., Boivin, A., Gan, L, Takase, Y, Labrie, F., St-Amand, J. (2009) Atlas of dihydrotestosterone actions on the transcriptome of prostate in vivo. The Prostate, 69: 293-316 |
Prostate Cancer |
2009 |
|
4707. Lévesque, M.H., El-Alfy, M., Cusan, L., Labrie, F. (2009) Androgen receptor as a potential sign of prostate cancer metastasis, The Prostate, 69: 1704-1711. |
Prostate Cancer |
2009 |
|
4708. Samson, M., Labrie, F., Zouboulis, C.C., Luu-The, V. (2010) Biosynthesis of dihydrotestosterone by a pathway that does not require testosterone as intermediate in the SZ95 sebaceous gland cell line. J Invest Derm. 130:602-604 |
Prostate Cancer |
2010 |
|
4723. Samson, M., Labrie, F., Luu-The, V. (2010) Sequential transformation of 4-androstenedione into dihydrotestosterone in prostate carcinoma (DU-145) cells indicates that 4-androstenedione and not testosterone is the substrate of 5alpha-reductase. Horm Mol Clin Invest. 1: 67-72. |
Prostate Cancer |
2010 |
|
4726. Pelletier, G., Luu-The, V., Tetu, B., Labrie, F. (1999) Immunocytochemical localization of type 5 17beta-hydroxysteroid dehydrogenase in human reproductive tissues. J. Histochem Cytochem., 47: 731-738. |
Prostate Cancer |
1999 |
|
4735. Labrie, F. (2010) Hormonal therapy of prostate cancer. In: Martini L, Chrousos GP, Labrie F, Pacak K, Pfaff De, eds. Pathological Situations and Diseases, Progress in Brain Research. Elsevier. Chapter 14, Vol. 182 321-341. |
Prostate Cancer |
2010 |
|
4750. Labrie, F. (2010) Editorial Comment: Kaliks RA et al. Complete androgen blockade safely allows for delay of cytotoxic chemotherapy in castration refractory prostate cancer. International Braz J Urol. 36: 306-307 |
Prostate Cancer |
2010 |
|
4753. Labrie, F. (2011) Blockade of testicular and adrenal androgens in prostate cancer treatment. Nature Reviews. 8: 73-80 |
Prostate Cancer |
2011 |
|
4754. Labrie, F (2011) DHEA and Cancer Risk or Prevention? In: DHEA (Dehydroepiandrosterone) in Human Health and Aging, R.R.Watson ed., Taylor & Francis Group LLC, publishers, Chapter 12, pp: 153-172. |
Prostate Cancer |
2011 |
|
4758. Yamana, K., Labrie, F., Luu-The, V (2010) Human type 3 5alpha-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride, Horm Mol Biol Clin Invest. 2:293-299. |
Prostate Cancer |
2010 |
|
4763. Labrie, F. (2011) Editorial: The major role of androgens in prostate cancer and the need for more efficient blockade. Expert Rev. Endocrinol. Metab. 6:313-316. |
Prostate Cancer |
2011 |
|
4770. Labrie, F. (2011) Blockade of all sources of androgens is key to optimal treatment at all stages of prostate cancer: Observations made in the 1980's are the basis of current progress in new drug development. Prostate Cancer Communication – Choices, 27: 3-10. |
Prostate Cancer |
2011 |